ArticleCurrent hepatology reports2019
NAFLD in women: Unique pathways, biomarkers and therapeutic opportunities.
Article in Current hepatology reports, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 20 citations in OpenAlex.
- Leisure-Time Physical Activity, Time Spent Sitting and Risk of Non-alcoholic Fatty Liver Disease: A Cross-Sectional Study in Puglia.Journal of general internal medicine · 2024Trial
- Metabolic dysfunction-associated steatotic liver disease across women's reproductive lifespan and issues.Clinical and molecular hepatology · 2025Article
- Non-linear association of the alanine aminotransferase to high-density lipoprotein cholesterol ratio with non-alcoholic fatty liver disease: a secondary analysis of a Chinese cohort.Frontiers in medicine · 2025Article
- Hypogonadism and nonalcoholic fatty liver disease.Endocrine · 2024Review
- Path analysis model to identify the effect of poor diet quality on NAFLD among Iranian adults from Amol Cohort Study.Scientific reports · 2024Article
- A comprehensive framework for managing metabolic dysfunction-associated steatotic liver disease: analyzing novel risk factors and advances in nanotechnology-based treatments and diagnosis.RSC medicinal chemistry · 2024Review
- Targeting chronic liver diseases: Molecular markers, drug delivery strategies and future perspectives.International journal of pharmaceutics · 2024Review
- Sex differences in metabolic dysfunction-associated steatotic liver disease: a narrative review.Ewha medical journal · 2024Review
- Sex differences in chronic liver disease and benign liver lesions.JHEP reports : innovation in hepatology · 2023Review
- The Role of Choline, Soy Isoflavones, and Probiotics as Adjuvant Treatments in the Prevention and Management of NAFLD in Postmenopausal Women.Nutrients · 2023Review
- Article
- Premenopausal Syndrome and NAFLD: A New Approach Based on Gender Medicine.Biomedicines · 2022Review
- Rodent models and metabolomics in non-alcoholic fatty liver disease: What can we learn?World journal of hepatology · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
Abstract
purpose of reviewIn this review article we evaluate sex differences in the natural history of NAFLD and highlight distinct risk profiles of women with NAFLD, as well as unique treatment considerations and research gaps. SUMMARY OF
findingsReproductive factors, such as menopausal status should be considered when evaluating NAFLD risk in women, as well as additional reproductive risk factors such as age at menarche, presence of polycystic ovary syndrome, and gestational diabetes. Women do appear to have lower risk for hepatocellular carcinoma from NASH, as well as lower mortality from NASH cirrhosis than men, although among women, NASH is now the leading indication for liver transplant. Data on sex differences in biomarker development and clinical trials are lacking, and researchers should be encouraged to evaluate biomarker performance by sex, and specifically report clinical trial endpoints in women.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.